Cadila Healthcare trades in green on the bourses

Cadila Healthcare is currently trading at Rs. 540.50, up by 9.15 points or 1.72% from its previous closing of Rs. 531.35 on the BSE.

The scrip opened at Rs. 537.00 and has touched a high and low of Rs. 544.10 and Rs. 531.25 respectively. So far 164810 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 673.70 on 12-May-2021 and a 52 week low of Rs. 358.10 on 11-Sep-2020.

Last one week high and low of the scrip stood at Rs. 566.85 and Rs. 524.00 respectively. The current market cap of the company is Rs. 54944.27 crore.

The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.22% and 9.90% respectively.

Zydus Cadila has received tentative approval from the USFDA to market Lenalidomide Capsules in the strengths of 2.5 mg, 5 mg,10 mg, 15 mg, 20 mg, and 25 mg. (USRLD: Revlimid). Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS).

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.